Sionna Therapeutics announced it will initiate a Phase 2 proof-of-concept trial for the combination of SION-451 and SION-2222 in late 2026, maintaining a strong cash position to support operations into 2029 despite discontinuing SION-719.
Sionna Therapeutics announced it will initiate a Phase 2 proof-of-concept trial for the combination of SION-451 and SION-2222 in late 2026, maintaining a strong cash position to support operations into 2029 despite discontinuing SION-719.